Search Bar & Filters
Found 64 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of the drug cemiplimab as adjuvant immunotherapy for patients with stage II-IIIA non-small cell lung cancer NSCLC who have had their tumors surgically removed and who have not received prior chemotherapy. This phase III trial focuses on comparing cemiplimab treatment to observation alone, specifically in patients whose tumors show PD-L1 expression of 1% or higher. The main goal is to measure disease-free survival, which means the time patients remain free from cancer recurrence or death. Participants in the experimental group receive cemiplimab intravenously at 350 mg every 3 weeks for 4 cycles, followed by 700 mg every 6 weeks for up to 6 cycles or until cancer returns or unacceptable side effects occur. Another group is assigned to observation without additional treatment. The study treatment schedules include specific dosing intervals and duration, designed to monitor the impact of cemiplimab on preventing cancer recurrence after surgery. Throughout the trial, participants will be monitored regularly for disease recurrence and side effects. Assessments include tracking disease-free survival and overall survival for up to approximately 59 months from randomization. Safety will be evaluated by documenting adverse events from the time of informed consent until the trial ends. Participants must comply with scheduled visits and testing to help researchers collect information on treatment effects and safety over the long term.
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combination therapy called BMS-986489 Atigotatug plus Nivolumab with Carboplatin and Etoposide compared to Atezolizumab with Carboplatin and Etoposide. This study focuses on participants with extensive-stage small cell lung cancer to understand which treatment works better as a first-line therapy. It is a Phase 3 clinical trial led by Bristol-Myers Squibb. Participants are randomly assigned to one of two groups one receiving the BMS-986489 combination with Carboplatin and Etoposide, and the other receiving Atezolizumab with Carboplatin and Etoposide. All medications are given at specific doses on designated days. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants undergo regular assessments including imaging scans to measure tumor size, and evaluations of overall survival over up to five years. Researchers also monitor symptoms, response duration, progression-free survival, and any adverse or serious side effects up to 135 days after treatment ends. The study includes detailed safety and efficacy tracking with multiple outcome measures to fully understand the impact of each treatment option.
Actively Recruiting
Researchers are conducting an international, multicenter, open-label phase III trial to evaluate the addition of adjuvant durvalumab after neoadjuvant chemotherapy combined with durvalumab and surgery in patients with early-stage, operable non-small cell lung cancer NSCLC stages IIB to IIIB. The main goal is to see if giving durvalumab after surgery improves disease-free survival in patients who do not achieve complete pathological response after initial treatment. The treatment plan involves 3 to 4 cycles of neoadjuvant durvalumab combined with platinum-based doublet chemotherapy, followed by surgery to remove the tumor. After surgery, patients with complete R0 or microscopic residual R1 resection are randomly assigned to either receive adjuvant durvalumab given intravenously at 1500 mg every 4 weeks for up to 12 cycles or to be observed without additional treatment. Participants will be monitored regularly for about 60 months after randomization to assess disease-free survival and other outcomes such as overall survival, time to recurrence, and treatment toxicity. Assessments include imaging scans to check for metastatic disease, pathological review after surgery, and ongoing safety evaluations. Participants must attend scheduled visits and follow study procedures throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating whether a combination of elranatamab, daratumumab, and lenalidomide provides better clinical benefits compared to a combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in people newly diagnosed with multiple myeloma who cannot have a transplant. This phase 3 study includes two parts the first focuses on safety, tolerability, and dose finding for elranatamab combinations, while the second compares treatment effectiveness and progression outcomes between the two combination therapies. Participants receive different drug combinations depending on the study part and assigned group. Part 1 evaluates elranatamab combined with daratumumab and lenalidomide or elranatamab with lenalidomide alone, focusing on dose levels. Part 2 randomly assigns participants to receive either elranatamab with daratumumab and lenalidomide or the comparator regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone. During the study, participants undergo regular assessments to monitor safety, treatment response, and disease progression, including measuring minimal residual disease negative complete response and progression-free survival. Researchers also track overall survival, adverse events, lab results, drug pharmacokinetics, and quality of life over an extended follow-up lasting up to approximately eight years after randomization.
Actively Recruiting
Researchers are evaluating whether antibiotic treatment is necessary for children with community-acquired pneumonia caused by the bacterium Mycoplasma pneumoniae. This trial compares the effects of a commonly used antibiotic, azithromycin, with a placebo in children aged 3 to 17 years. The study addresses concerns about increasing antibiotic resistance and aims to improve treatment decisions for this common cause of pneumonia in children. Participants are randomly assigned to receive either azithromycin or a placebo for five days. The azithromycin group takes a daily dose of 10mgkg on the first day followed by 5mgkg on days 2 through 5. This randomized, double-blind, placebo-controlled trial takes place across multiple pediatric centers and includes both ambulatory and hospitalized children. The study involves initial screening to confirm Mycoplasma pneumoniae infection using a specific antibody test before starting the assigned treatment. During the study, researchers will monitor symptom duration, vital signs, and changes in patient care status for up to 28 days. They will also assess overall clinical outcomes, symptom resolution, quality of life impacts on the family, time to return to normal daily activities, and the development of any complications related to the infection. Follow-up includes clinical examinations and parent reports to track progress and safety throughout the study period.
Actively Recruiting
Researchers are evaluating an experimental drug called odronextamab in adults with previously untreated follicular lymphoma, a type of non-Hodgkin lymphoma. The study consists of two parts Part 1 focuses on assessing the safety and tolerability of odronextamab alone, while Part 2 compares odronextamab to rituximab combined with chemotherapy, which is the current standard treatment. The research also explores side effects, drug levels in the blood, immune responses against the drug, and effects on quality of life and daily activities. Participants in Part 1 receive only odronextamab. In Part 2, participants are randomly assigned to one of two groups one group receives odronextamab followed by maintenance treatment with the same drug, and the other group receives rituximab combined with chemotherapy followed by rituximab maintenance. Chemotherapy options include combinations of cyclophosphamide, doxorubicin, vincristine, prednisone, and bendamustine, administered as described in the study protocol. Throughout the study, participants undergo regular assessments including imaging scans to measure disease, blood tests to monitor drug levels and immune response, and evaluations of physical function and quality of life. Researchers track adverse events and treatment responses up to five years. Safety and effectiveness are closely monitored, with key outcomes measured at intervals up to 30 months and beyond. The total participation time varies depending on treatment and follow-up schedules.
Actively Recruiting
Researchers are analyzing the outcomes and side effects experienced by patients undergoing radiation therapy. This observational study uses a database of patient records from the year 2000 to 2025 to systematically record and evaluate treatment results and adverse events. The goal is to improve the quality of radiotherapy and reduce serious side effects for future patients through detailed data analysis and quality control. The study collects data from patients treated with radiotherapy at the Department of Radiation Oncology at the Winterthur Cantonal Hospital. It focuses on tracking overall survival and progression-free survival over 25 years, while also identifying risk factors that influence treatment outcomes. The study also monitors both acute and late adverse events related to radiation therapy. Participants personal and treatment-related data are systematically recorded and analyzed to assess the effectiveness and safety of radiotherapy. The study evaluates outcomes such as survival rates and side effects to inform future improvements in care. This long-term data collection and analysis supports quality assurance and contributes to clinical research at the Institute for Radio-Oncology.
Actively Recruiting
This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events. Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks. During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.
Actively Recruiting
Healthy Volunteer
Researchers are studying women who are pre- and perimenopausal with a uterus to understand how ultrasound features of the myometrium relate to symptoms of adenomyosis. Adenomyosis is a condition where endometrial tissue grows within the uterine muscle, often causing pain, abnormal bleeding, and fertility issues. This observational study aims to link ultrasound signs with symptom severity and develop a grading system to better assess disease impact. Participants will have a routine gynecological ultrasound exam during which ultrasound features are recorded. They will also complete a questionnaire about their pain and bleeding patterns. There are no treatments or interventions, and this study involves only a single visit during their scheduled ultrasound appointment. Throughout the study, researchers will collect ultrasound data and symptom information to analyze the relationship between imaging features and clinical symptoms. The primary focus is on pain scores and bleeding severity. Data will be entered into patient files and analyzed within one month. The study plans to enroll 1000 women over three years across multiple centers, including 400 from Switzerland.
1-10 of 64
1